Seeking Alpha

Cordis Announces Positive Results from Two Major Studies Demonstrating Durable Efficacy of SELUTION SLR™ Drug-Eluting Balloon in Complex Peripheral Artery Disease Patients

SELUTION SLR™ Drug-Eluting Balloon (DEB) achieves amongst the highest reported patency for any drug-eluting or drug-coated technology at 3 years in the SELUTION SFA Japan Trial, with 81.5% primary ...
TCTMD

Cordis Announces Positive 24-Month Results from Superficial Femoral Artery Study, Confirming Sustained Benefits of SELUTION SLR™ (sustained limus release) Drug-Eluting ...

MIAMI LAKES, Fla., June 18, 2024 /PRNewswire/ -- Cordis, a global leader in the development and manufacturing of interventional cardiovascular and endovascular technology, today announces positive ...